Brand-name drug · growth hormone-releasing factor (GHRF) analog

Egrifta (tesamorelin)

From the FDA label, read Published by PepVault

Egrifta is tesamorelin from Theratechnologies, a daily injection that acts like the body’s own signal for releasing growth hormone; it is sold today as Egrifta SV and Egrifta WR.

FDA approved it for one use: reducing excess abdominal fat in adults with HIV who have lipodystrophy, a change in how the body stores fat.

Active ingredient
Tesamorelin
Maker
Theratechnologies
Class
growth hormone-releasing factor (GHRF) analog
FDA application
BLA 022505, first approved 2010

What FDA approved it for

The label is explicit about what Egrifta is not: it is not a weight-loss medicine, because its effect on weight is neutral, and its long-term heart safety has not been established. It also notes no evidence that it helps people keep to their HIV medicines.

For someone who hasn’t lost belly fat on it, the label asks the prescriber to weigh whether to continue.

From the label: 2.1 Recommended Dosage and Administration Instructions; 1 Indications and Usage.

How it is supplied

Egrifta’s forms and the doses each one gives, as the label lists them
FormDoses
Egrifta SV vial (powder)2 mg per vial
Egrifta WR vial (powder)11.6 mg per vial

From the label: 3 Dosage Forms and Strengths.

The label’s dosing schedule

This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.

Egrifta SV, once a day

Egrifta SV, once a day: one dose on the label, 1.4 mg.
DoseWhen, on the label
1.4 mg a dayEvery day

Egrifta WR, once a day

Egrifta WR, once a day: one dose on the label, 1.28 mg.
DoseWhen, on the label
1.28 mg a dayEvery day

Egrifta has no climb: each form is one dose a day from the start. Egrifta WR’s 1.28 mg and Egrifta SV’s dose differ because the formulations differ, which is why the label says one can’t stand in for the other.

From the label: 2.1 Dosage and Administration; 2.1 Recommended Dosage and Administration Instructions.

How it’s taken

Both forms are powders mixed with the water that comes in the box, then injected under the skin of the belly once a day, moving around the belly and avoiding scars, bruises and the navel.

The two forms are not interchangeable. Egrifta SV is mixed fresh for each daily dose and used at once; one mixed Egrifta WR vial covers 7 days in a row and is thrown away 7 days after mixing.

From the label: 2.1 Recommended Dosage and Administration Instructions; 2.2 Reconstitution Procedure.

A smiling woman in a dark training top in her kitchen, holding a glass of water

PepVault for iPhone

Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

If a dose is missed

Egrifta’s label gives no instruction for a missed dose; a prescriber or pharmacist can answer for a given case.

Storage

Unmixed vials of either form are kept at room temperature, 68°F to 77°F, in the original box away from light.

A mixed Egrifta WR vial also stays at room temperature and is never frozen; a mixed Egrifta SV dose is used straight away, not kept in the fridge.

From the label: 16 How Supplied/Storage and Handling; 2.2 Reconstitution Procedure.

Side effects and warnings

Adverse reactions more frequent on Egrifta than on placebo in the first 26 weeks of the trials (first eight rows). Percent of people.
ReactionPlaceboEgrifta
Injection site reaction617
Joint pain (arthralgia)1113
Pain in arms or legs56
Muscle pain (myalgia)26
Swelling of the legs or feet26
Tingling (paresthesia)25
Reduced feeling (hypoesthesia)24
Rash24

The pooled trials gave Egrifta to 543 people and placebo to 263; reactions where the shot goes in were the most common, in 17% against 6%.

The other warnings

Egrifta has no boxed warning. Its warnings cover a possible risk of cancer growth (it raises growth hormone and IGF-1, so the label rules it out with active cancer), raised IGF-1 levels, fluid retention, higher blood sugar or diabetes, allergic reactions, reactions at the injection site, and a higher risk of death in people who are acutely critically ill. It must not be used in pregnancy or with a disrupted hypothalamic-pituitary axis.

From the label: 6.1 Clinical Trials Experience; 5 Warnings and Precautions.

What else we have on tesamorelin

Questions about Egrifta

What is the dose of Egrifta?

One dose a day, injected into the belly: 1.4 mg for Egrifta SV, or 1.28 mg for Egrifta WR. The two forms are not interchangeable. A prescriber sets the dose.

Is Egrifta a weight-loss drug?

No. Its label approves it only for reducing excess belly fat in adults with HIV and lipodystrophy, and says it is not for weight loss because its effect on weight is neutral.

What is the difference between Egrifta SV and Egrifta WR?

Egrifta SV comes as a 2 mg vial mixed fresh for each 1.4 mg daily dose. Egrifta WR comes as an 11.6 mg vial; once mixed, it gives daily 1.28 mg doses for 7 days.

How is Egrifta stored?

The unmixed vials stay at room temperature, 68°F to 77°F, in the original box away from light.

Sources

PepVault is not affiliated with Theratechnologies. Egrifta is a trademark of its owner.

PepVault for iPhone

Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo